Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 14:101–12.

Arai T, Sakurai U, Sawabe M, Honma N, Aida J, Ushio Y, et al. Frequent microsatellite instability in papillary and solid–type, poorly differentiated adenocarcinomas of the stomach. Gastric Cancer. 2013;16:505–12.

Article  CAS  PubMed  Google Scholar 

Hirai H, Yoshizawa T, Morohashi S, Haga T, Wu YY, Ota R, et al. Clinicopathological significance of gastric poorly differentiated medullary carcinoma. Biomed Res-Tokyo. 2016;37:77–84.

Article  CAS  Google Scholar 

Arai T, Matsuda Y, Aida J, Takubo K, Ishiwata T. Solid–type poorly differentiated adenocarcinoma of the stomach: clinicopathological and molecular cha. Gastric Cancer. 2019;22:314–22.

Article  CAS  PubMed  Google Scholar 

Tsuruta S, Kohashi K, Yamada Y, Fujiwara M, Koga Y, Ihara E, et al. Solid–type poorly differentiated adenocarcinoma of the stomach: deficiency of mismatch repair and SWI/SNF complex. Cancer Sci. 2020;111:1008–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sasaki T, Kohashi K, Kawamoto S, Ihara E, Oki E, Nakamura M, et al. Tumor progression by epithelial–mesenchymal transition in ARID1A– and SMARCA4–aberrant solid–type poorly differentiated gastric adenocarcinoma. Virchows Arch. 2022;480:1063–75.

Article  CAS  PubMed  Google Scholar 

Kawatoko S, Kohashi K, Torisu T, Sasaki T, Umekita S, Oki E, et al. Solid–type poorly differentiated adenocarcinoma of the stomach: a characteristic morphology reveals a distinctive immunoregulatory tumor microenvironment. Pathol Res Pract. 2022;238:154124.

Article  CAS  PubMed  Google Scholar 

Umekita S, Kiyozawa D, Kohashi K, Kawatoko S, Sasaki T, Ihara E, et al. Clinicopathological significance of microsatellite instability and immune escape mechanism in patients with gastric solid–type poorly differentiated adenocarcinoma. Gastric Cancer. 2024;27:484–94.

Article  CAS  PubMed  Google Scholar 

Huang B, Lang X, Li X. The role of IL–6/JAK2/STAT3 signaling pathway in cancers. Front Oncol. 2022;16:1023177.

Article  Google Scholar 

Zheng L, Chen J, Zhou Z, He Z. Knockdown of long non–coding RNA HOXD–AS1 inhibits gastric cancer cell growth via inactivating the JAK2/STAT3 pathway. Tumour Biol. 2017;39:1010428317705335.

Article  PubMed  Google Scholar 

Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 2004;23:4921–9.

Article  CAS  PubMed  Google Scholar 

Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, et al. Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS One. 2014;9:e95993.

Article  PubMed  PubMed Central  Google Scholar 

Ayele TM, Muche ZT, Teklemariam AB, Kassie AB, Abebe EC. Role of JAK2/STAT3 signaling pathway in the tumorigenesis, chemotherapy resistance, and treatment of solid tumors: a systemic review. J Inflamm Res. 2022;15:1349–64.

Article  Google Scholar 

Yakata Y, Nakayama T, Yoshizaki A, Kusaba T, Inoue K, Sekine I. Expression of p–STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int J Oncol. 2007;30:437–42.

CAS  PubMed  Google Scholar 

Kim DY, Cha ST, Ahn DH, Kang HY, Kwon CI, Ko KH, et al. STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol. 2009;24:646–51.

Article  CAS  PubMed  Google Scholar 

Deng JY, Sun D, Liu XY, Pan Y, Liang H. STAT–3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol. 2010;16:5380–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu LJ, Li HX, Luo XT, Lu RZ, Ma YF, Wang R, et al. STAT3 activation in tumor cell–free lymph nodes predicts a poor prognosis for gastric cancer. Int J Clin Exp Pathol. 2014;7:1140–6.

PubMed  PubMed Central  Google Scholar 

Ullrich KAM, Schulze LL, Paap EM, Muller TM, Neurath MF, Zundler S. Immunology of IL–12: an update of functional activities and implications for disease. Exceli J. 2020;19:1563–89.

Google Scholar 

Yang C, Mai H, Peng J, Zhou B, Hou J, Jiang D. STAT4: an immunoregulator contributing to diverse human diseases. Int J Biol Sci. 2020;2020(16):1575–85.

Article  Google Scholar 

Frucht DM, Aringer M, Galon J, Danning C, Brown M, Fan S, et al. STAT4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1–mediated inflammation. J Immunol. 2000;164:4659–64.

Article  CAS  PubMed  Google Scholar 

Zhou X, Xia Y, Su J, Zhang G. Down–regulation of miR–141 induced by helicobacter pylori promotes the invasion of gastric cancer by targeting STAT4. Cell Physiol Biochem. 2014;33:1003–12.

Article  CAS  PubMed  Google Scholar 

Xiong H, Du W, Wang JL, Wang YC, Tang JT, Hong J, et al. Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J Mol Med (Berl). 2012;90:1037–46.

Article  CAS  PubMed  Google Scholar 

Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X. IL–6 secreted by cancer–associated fibroblasts promotes epithelial–mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget. 2017;8:20741–50.

Article  PubMed  PubMed Central  Google Scholar 

Yang Y, Shi Z, Bai R, Hu W. Heterogeneity of MSI–H gastric cancer identifies a subtype with worse survival. J Med Genet. 2021;58:12–9.

Article  CAS  PubMed  Google Scholar 

Nishi M, Batsaikhan BE, Yoshikawa K, Higashijima J, Tokunaga T, Takasu C, et al. High STAT4 expression indicates better disease–free survival in patients with gastric cancer. Anticancer Res. 2017;37:6723–9.

CAS  PubMed  Google Scholar 

Zhang Y, Yu C. Prognostic values of signal transducers activators of transcription in gastric cancer. Biosci Rep. 2019;39:BRS20181695.

Article  Google Scholar